Ratings Surperformance

Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
-

Ratings ESG MSCI

Ratings Macro Group Pharmaceuticals (Macro Capital) S.A.E: Strengths and Weaknesses

  • The company's MSCI ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Highlights: Macro Group Pharmaceuticals (Macro Capital) S.A.E
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • Analyst opinion has improved significantly over the past four months.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Rating Financials

Macro Group Pharmaceuticals (Macro Capital) S.A.E SectorEgypt

Fundamentals

-

Growth

-

Revenue growth

-

EPS growth

-

FCF growth

-

Profitability

-

EBITDA Margin

-

EBIT Margin

-

Net Margin

-

Capital Efficiency

-

ROA

-

ROCE

-

ROE

-

Financial Health

-

Gearing

-

Leverage

-

Capital Intensity

-

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

-

Long term EPS growth

-
More ratings

Rating Valuation

Macro Group Pharmaceuticals (Macro Capital) S.A.E SectorEgypt

Global Valuation

-

Enterprise Value

-

EV/Revenue

-

EV/EBITDA

-

EV/FCF

-

Equity Valuation

-

P/E

PBR

-

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

-
More ratings

Rating Consensus

Macro Group Pharmaceuticals (Macro Capital) S.A.E SectorEgypt

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

-

Analysts' target price evolution (4 months)

-

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Macro Group Pharmaceuticals (Macro Capital) S.A.E SectorEgypt

Visibility

-

Analysts' coverage

-

Financial estimates divergence

-

Analysts' recommendations divergence

Analysts' Target price divergence

-

Surprise rates

-

Rating Revisions

Macro Group Pharmaceuticals (Macro Capital) S.A.E SectorEgypt

Financial revisions

-

Revenue revisions (1 year)

-

Revenue revisions (4 months)

-

EPS revisions (1 year)

-

EPS revisions (4 months)

-

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
17.86M - - - - - -
1,057B
A
625B -
BBB
- -
435B
AA
-
363B
AA
296B
AAA
249B
A
222B
A
209B
A
165B
AA
Average 362.08B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. MCRO Stock
  4. Ratings Macro Group Pharmaceuticals (Macro Capital) S.A.E